Seeking Alpha

kpcapitalpartners

kpcapitalpartners
Send Message
View as an RSS Feed
View kpcapitalpartners' Comments BY TICKER:
Latest  |  Highest rated
  • 5 BioPharmas With Near-Term Catalysts [View article]
    Cramer a genius...? You must be kidding me! Are you a comedian? He's a genius of a self-promoter, but that's about it. You must be 1 of the "sheeple" that blindly follows whatever he spews out of his mouth. I thank God that there are so many members of Cramer's Cult. It makes my job of making $ much easier.
    Oct 14 12:17 PM | 1 Like Like |Link to Comment
  • New CEO Should Right InVivo's Ship [View article]
    I feel badly for those who are down significantly in their NVIV investment. However, I find it incomprehensible that any hard-working person would invest their "life savings" in an extremely speculative, small company. To describe this as reckless and ill-informed is the ultimate understatement.
    Oct 14 12:10 PM | Likes Like |Link to Comment
  • New CEO Should Right InVivo's Ship [View article]
    You make some very valid points. It would be great to hear the company's management address them. Why the hell have there been no class action suits filed? Beyond my comprehension...
    Oct 9 10:06 PM | Likes Like |Link to Comment
  • New CEO Should Right InVivo's Ship [View article]
    Jason: Uplisting is probably on the back burner and/or unrealistic anytime in the near future. Did you address it w/management?

    Have to agree w/Jo Teng. Am stunned that NVIV isn't fielding lawsuits & inquiries from every ambulance chaser around...QCOR & UNXL were absolutely inundated...& they are both legit. I guess that Citron hasn't yet gotten involved, huh?

    Thanks for posting & pay no attention to clueless ARNA Investor.
    Oct 9 03:46 PM | 2 Likes Like |Link to Comment
  • Rockwell Medical- A Highly Undervalued Gem [View instapost]
    Great job! Thank you for going to all the effort & sharing with us. I have built a large position in RMTI during the past 2 months & share your positive outlook for the company. I considered last week's sell-off a great opportunity to add to my position & did so aggressively on Friday.

    Best of luck,

    Ken
    Sep 23 12:45 AM | 2 Likes Like |Link to Comment
  • Bullish On Halozyme: Short-Term Catalysts And A Large Buy By A Jazz Pharma Director [View article]
    Scott/Kyle: Thanks a lot for posting. Great article! I've built a large position in HALO over the past month. (Wish I had become familiar with the story a lot earlier, but am sure glad that I found it).

    While TKMR is at an earlier stage in its life-cycle and much more limited in its partnerships than is HALO, I'm bullish on the company's drug delivery technology, along with future partnership and royalty stream potential. We'll see what happens...

    Your continued input has helped me out greatly.

    Ken
    Sep 17 09:24 PM | 1 Like Like |Link to Comment
  • NeoStem Continues To Soar Behind A Slew Of Key Developments [View article]
    I own SSH (my 3rd most heavily-weighted position) & am buying NBS for the first time today below $8.20. I believe that people are really missing an important point. SSH & NBS can be complementary CHF therapies. I'm convinced that SSH's primary competitors are THOR & HTWR, not NBS. It isn't at all a case of SSH vs. NBS. Just my 2 cents...
    Sep 16 03:27 PM | 3 Likes Like |Link to Comment
  • Gentium: Several Underappreciated Investment Positives [View article]
    Thanks for your input. Very valuable. I have established a large position in GENT during the past 2 months & continue to add on pullbacks. View it as a great opportunity. Under-followed & under-appreciated.

    The fact that I am the 1st to comment on your article probably confirms my observation regarding GENT's obscurity. That's great by me for now. Hopefully we'll have a few more opportunities to buy on weakness prior to upcoming catalysts & breakout to the upside!
    Sep 14 08:42 PM | 1 Like Like |Link to Comment
  • Seeking The Best Opportunities In Biotech By Value [View article]
    I am in total agreement. Additionally, due to the limited number of world-wide potential Juxtapid patients, AEGR can efficiently & effectively role-out out the drug. The author's argument that Sanofi can better market Kynmaro due to its size/financial resources is flawed. He obviously did not participate in management's last quarterly call...
    Sep 3 02:40 PM | Likes Like |Link to Comment
  • Seeking The Best Opportunities In Biotech By Value [View article]
    Guess you didn't listen to AEGR management's last conference call...
    Sep 3 02:36 PM | Likes Like |Link to Comment
  • A Fresh Dose Of Reality From InVivo [View article]
    What??? You are obviously one clueless clown. Jason is 1 of 2 analysts (and the only credible analyst) following NVIV. His updates, reports, opinions, etc. carry a lot of weight.

    It's too bad that you're not smart enough to figure that out. Please - for your own sake - stick to mutual funds, CDs, and a bank savings account.
    Aug 27 04:15 PM | 4 Likes Like |Link to Comment
  • A Fresh Dose Of Reality From InVivo [View article]
    Jason:

    Thanks for the update. By removing you as a listed analyst, it is my view that NVIV has lost a great deal of credibility. From what I've read and experienced regarding the company's now ex-CEO, I think that NVIV had better get ready for a big-time shareholder class action suit.
    Aug 27 12:11 PM | Likes Like |Link to Comment
  • InVivo Therapeutics - Reality Distortion Or Reformation? [View article]
    Thanks much for your article! I'm familiar with numerous hatchet-jobs by shorts which were very similar to BS's attack on NVIV. QCOR and UNXL immediately come to mind. Was able to capitalize on the collapse of both companies' stock price.

    I took an initial position in NVIV on Friday afternoon & accumulated 6300 shares. Will continue to add to the position on further weakness. I viewed Friday's sell-off as a worthwhile opportunity to buy NVIV on sale.

    It remains to be seen whether or not the leadership change will hasten an uplisting, but I am in agreement that a new CEO will be a positive.

    If anyone can provide info regarding NVIV's possible uplisting and whether or not it is realistic to expect it prior to year-end, I would really appreciate any insight.
    Aug 26 06:32 PM | 1 Like Like |Link to Comment
  • Understanding The EPA's RFS2, Its Future, RINs And The Ethanol Blend Wall Pt #2 [View article]
    I agree. REGI's flexibility regarding feedstock is definitely appealing to me. Just bought 500 more shares @ $12.90-12.92. Have taken advantage of pullbacks during the past several months to add to position.

    By the way, thanks a lot for your input. Your articles have been very valuable to me.

    Ken
    Aug 19 01:50 PM | 1 Like Like |Link to Comment
  • Understanding The EPA's RFS2, Its Future, RINs And The Ethanol Blend Wall Pt #2 [View article]
    Something must be going on in D.C. today. Anyone have any info?
    Aug 19 11:42 AM | Likes Like |Link to Comment
COMMENTS STATS
110 Comments
137 Likes